LIMN
Price
$3.11
Change
-$0.01 (-0.32%)
Updated
Oct 22 closing price
Capitalization
4.18M
21 days until earnings call
Intraday BUY SELL Signals
UPB
Price
$2.99
Change
+$0.19 (+6.79%)
Updated
Oct 22 closing price
Capitalization
163.77M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LIMN vs UPB

LIMN vs UPB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LIMN vs. UPB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIMN is a StrongBuy and UPB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LIMN with price predictions
Oct 22, 2026

LIMN in +4.59% Uptrend, growing for three consecutive days on October 20, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LIMN advanced for three days, in 50 of 88 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for LIMN just turned positive on September 22, 2026. Looking at past instances where LIMN's MACD turned positive, the stock continued to rise in 22 of 49 cases over the following month. The odds of a continued upward trend are 45%.

LIMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LIMN as a result. In 33 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 31%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for LIMN entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.896) is normal, around the industry mean (2.973). P/E Ratio (-0.130) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. LIMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for UPB with price predictions
Oct 22, 2026

UPB in -19.30% downward trend, sliding for three consecutive days on October 16, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where UPB declined for three days, in 87 of 99 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for UPB turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In 18 of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The Aroon Indicator for UPB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in 85 of 101 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

UPB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.604) is normal, around the industry mean (2.973). P/E Ratio (-1.038) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
LIMNUPB
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
31%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
45%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
62%
Aroon
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (LIMN: $3.12 vs. UPB: $2.80)
Brand notoriety: LIMN and UPB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LIMN: 474% vs. UPB: 168%
Market capitalization -- LIMN: $4.18M vs. UPB: $163.77M
LIMN [@Biotechnology] is valued at $4.18M. UPB’s [@Biotechnology] market capitalization is $163.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LIMN’s FA Score shows that 1 FA rating(s) are green while UPB’s FA Score has 1 green FA rating(s).

  • LIMN’s FA Score: 1 green, 4 red.
  • UPB’s FA Score: 1 green, 4 red.
According to our system of comparison, UPB is a better buy in the long-term than LIMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LIMN’s TA Score shows that 4 TA indicator(s) are bullish while UPB’s TA Score has 4 bullish TA indicator(s).

  • LIMN’s TA Score: 4 bullish, 3 bearish.
  • UPB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, LIMN is a better buy in the short-term than UPB.

Price Growth

LIMN (@Biotechnology) experienced а -4.00% price change this week, while UPB (@Biotechnology) price change was -18.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

LIMN is expected to report earnings on Nov 12, 2026.

UPB is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LIMN
Daily Signal:
Gain/Loss:
UPB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

LIMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LIMN has been loosely correlated with FTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if LIMN jumps, then FTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIMN
1D Price
Change %
LIMN100%
-0.32%
FTH - LIMN
35%
Loosely correlated
-2.28%
UPB - LIMN
35%
Loosely correlated
+6.79%
IMMP - LIMN
34%
Loosely correlated
-3.66%
RNA - LIMN
32%
Poorly correlated
+2.00%
ALDX - LIMN
31%
Poorly correlated
-3.73%
More

UPB and

Correlation & Price change

A.I.dvisor indicates that over the last year, UPB has been loosely correlated with IMNM. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UPB
1D Price
Change %
UPB100%
+6.79%
IMNM - UPB
36%
Loosely correlated
+1.44%
ARVN - UPB
36%
Loosely correlated
+2.18%
LIMN - UPB
35%
Loosely correlated
-0.32%
IRON - UPB
34%
Loosely correlated
-1.28%
SLDB - UPB
34%
Loosely correlated
-3.43%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRBK64.944.26
+7.02%
Green Brick Partners
COKE214.935.24
+2.50%
Coca-Cola Consolidated Inc
FLGT19.99-0.14
-0.70%
Fulgent Genetics
HOVR1.30-0.04
-3.33%
New Horizon Aircraft Ltd
SOS0.22-0.01
-3.91%
SOS Limited